ASO Visual Abstract: Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/N0 HER2-Amplified Breast Cancer

Annals of Surgical Oncology ◽

10.1245/s10434-021-11312-3 ◽

2022 ◽

Author(s):

Emilie D. Duchesneau ◽

Selena J. An ◽

Paula D. Strassle ◽

Katherine Reeder-Hayes ◽

Kristalyn K. Gallagher ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Clinical Predictors

Download Full-text

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer

Oncology Letters ◽

10.3892/ol.2017.6692 ◽

2017 ◽

Vol 14 (4) ◽

pp. 4135-4141 ◽

Cited By ~ 11

Author(s):

Ayako Nakashoji ◽

Akira Matsui ◽

Aiko Nagayama ◽

Yuko Iwata ◽

Manami Sasahara ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Pathological Complete Response ◽

Complete Response ◽

Clinical Predictors ◽

Response To Neoadjuvant Chemotherapy

Download Full-text

Exclusive radiation therapy after neoadjuvant chemotherapy for locally advanced breast cancer: experience of a single academic institution

European Journal of Cancer ◽

10.1016/s0959-8049(02)80501-9 ◽

2002 ◽

Vol 38 (11) ◽

pp. S150

Author(s):

J Caudrelier

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Neoadjuvant Chemotherapy ◽

Advanced Breast Cancer ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Academic Institution ◽

Advanced Breast ◽

Cancer Experience

Download Full-text

Association between gastrin-releasing peptide receptor expression based on Ga-68-RM2-PET and histopathological tumor regression after neoadjuvant chemotherapy in primary breast cancer

10.1055/s-0039-1683576 ◽

2019 ◽

Author(s):

C Stoykow ◽

J Asberger ◽

H Maecke ◽

P Bronsert ◽

M Werner ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Primary Breast Cancer ◽

Tumor Regression ◽

Receptor Expression ◽

Peptide Receptor ◽

Gastrin Releasing Peptide

Download Full-text

Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS+EG score

10.1055/s-0039-1688026 ◽

2019 ◽

Author(s):

L Michel ◽

L Sommer ◽

R González Silos ◽

J Lorenzo Bermejo ◽

A von Au ◽

...

Keyword(s):

Breast Cancer ◽

Risk Assessment ◽

Neoadjuvant Chemotherapy ◽

Primary Breast Cancer ◽

Clinical Utility

Download Full-text

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy: Sequential analysis

10.26226/morressier.596dfd55d462b80292386fa4 ◽

2017 ◽

Author(s):

You-Jeong Seo

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Sequential Analysis ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Pik3ca Mutations ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Ki-67 CAN BE USED AS A PREDICTIVE FACTOR FOR THE EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS

10.26226/morressier.599bdc7ad462b80296ca087f ◽

2017 ◽

Author(s):

Nejc Kozar

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Predictive Factor ◽

Breast Cancer Patients ◽

Ki 67

Download Full-text

3 / The value of tumour infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a study in a hospital complex

10.26226/morressier.5b4709876f4cb30010951a18 ◽

2018 ◽

Author(s):

Alicia Cordoba ◽

Alicia ['Tania'] ◽

David Guerrero Setas

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Tumour Infiltrating Lymphocytes ◽

Infiltrating Lymphocytes ◽

Response To Neoadjuvant Chemotherapy

Download Full-text

Atorvastatin in Treating Patients With Stages IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Case Medical Research ◽

10.31525/ct1-nct03872388 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Pathologic Complete Response ◽

Complete Response

Download Full-text

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct03982485 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy

Download Full-text

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04290793 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Her 2

Download Full-text